Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6682160rdf:typepubmed:Citationlld:pubmed
pubmed-article:6682160lifeskim:mentionsumls-concept:C0332437lld:lifeskim
pubmed-article:6682160lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:6682160lifeskim:mentionsumls-concept:C0272293lld:lifeskim
pubmed-article:6682160lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:6682160lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:6682160lifeskim:mentionsumls-concept:C0021022lld:lifeskim
pubmed-article:6682160pubmed:issue1lld:pubmed
pubmed-article:6682160pubmed:dateCreated1983-5-27lld:pubmed
pubmed-article:6682160pubmed:abstractTextWe examined the effectiveness of a high-dose Immunglobulin therapy in 8 patients with idiopathic thrombocytopenic purpura (ITP) and measured the number, the morphology and the function of Thrombocytes as well as thrombocyte dependent clotting parameters. 0.5 g/kg/B.W. 7s-Immunglobulin (7s-IgG) per treatment led to normal thrombocyte numbers in 7 out of 8 patients. The maximal thrombocyte-rise occurred on the 4th-10th day of treatment. Simultaneously bleeding time, thrombocyte-volume distribution frequency and Ristozetin-ADP and Collagen induced thrombocyte-aggregation normalized-indication as well as cause of the 7s-IgG-therapy are discussed.lld:pubmed
pubmed-article:6682160pubmed:languagegerlld:pubmed
pubmed-article:6682160pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6682160pubmed:citationSubsetIMlld:pubmed
pubmed-article:6682160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6682160pubmed:statusMEDLINElld:pubmed
pubmed-article:6682160pubmed:issn0300-8630lld:pubmed
pubmed-article:6682160pubmed:authorpubmed-author:GrafNNlld:pubmed
pubmed-article:6682160pubmed:authorpubmed-author:MüllerJJlld:pubmed
pubmed-article:6682160pubmed:authorpubmed-author:WahlenWWlld:pubmed
pubmed-article:6682160pubmed:authorpubmed-author:NienhausK HKHlld:pubmed
pubmed-article:6682160pubmed:issnTypePrintlld:pubmed
pubmed-article:6682160pubmed:volume195lld:pubmed
pubmed-article:6682160pubmed:ownerNLMlld:pubmed
pubmed-article:6682160pubmed:authorsCompleteYlld:pubmed
pubmed-article:6682160pubmed:pagination17-23lld:pubmed
pubmed-article:6682160pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:meshHeadingpubmed-meshheading:6682160-...lld:pubmed
pubmed-article:6682160pubmed:articleTitle[Thrombocyte morphology and function during high-dose immunoglobulin therapy in acute and chronic idiopathic thrombocytopenic purpura. 1].lld:pubmed
pubmed-article:6682160pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6682160pubmed:publicationTypeEnglish Abstractlld:pubmed